Pfizer Inc
NYSE: PFE
$26.17
+$0.52 (+2.0%)
Closing Price on November 25, 2024
PFE Articles
One of Cathie Wood's ARK Invest funds bought over 150,000 shares of Pfizer on August 18.
Published:
Tuesday's top analyst upgrades and downgrades included AbbVie, Alibaba, American Airlines, AT&T, Chipotle Mexican Grill, JD.com, Kimberly-Clark, Pfizer, Starbucks and Weyerhaeuser.
Published:
Two Dow Jones industrial average components report quarterly earnings before markets open Wednesday, along with a cannabis company that gets some attention as a meme stock.
Published:
Thursday's top analysts upgrades and downgrades included Apple, Darden Restaurants, Peloton, Pfizer, Pioneer Natural Resources, Tilray and Zynga.
Published:
Two alternative energy companies report March quarter earnings after the closing bell Monday, and three other noteworthy reports are due before Tuesday's opening bell.
Published:
24/7 Wall St. looks at some big analyst calls that we have seen so far on Wednesday, including Abercrombie & Fitch, Pfizer and Teva Pharmaceutical.
Published:
Thursday's top analyst upgrades and downgrades included Apple, Best Buy, Electronic Arts, FireEye, Match, PayPal, Qualcomm and ViacomCBS.
Published:
These five outstanding stocks are rated Buy, have a least a 4% dividend and offer investors a degree of relative safety. They make sense for growth and income investors while the stock market is...
Published:
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.
Published:
Myovant shares shot up on Monday after the company announced a new collaboration with Pfizer for its tumor treatment across a couple of indications.
Published:
Wednesday's top analyst upgrades and downgrades included Chipotle Mexican Grill, Etsy, Exxon Mobil, General Electric, Jazz Pharmaceuticals, Microsoft, Nikola, Palo Alto Networks, Pfizer and Twitter.
Published:
BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
Published:
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
Published:
COVID-19 stocks were on the move on Wednesday after a few huge updates in regards to vaccine approval.
Published:
Here is an update on the stocks of each major player in the COVID-19 arena, including brief trading histories and consensus price targets.
Published: